Can Globus Medical Stock Rally 30% After This Dip?
Globus Medical (GMED) shares fell 19.1% since November 4, 2026, after lowering its 2026 revenue forecast. Historically, the stock has rallied a median 39.3% within a year after similar drops. Revenue declined 0.7% in Q3 2026, with full-year revenue forecast cut to $3.09B. Management expects new products to drive growth in 2027.
How this was made

The 30-second read
Why it matters
It argues a potential rebound depends on whether new spine products like SCRIPT begin adding to sales, while current guidance points to no meaningful growth contribution until 2027 and a mid-single-digit Q4 sales decline.
Market read
For traders, the actionable takeaway is the guidance-driven growth delay and the February 2027 earnings catalyst for U.S. Spine growth, rather than a near-term event.
What to watch
The piece emphasizes SCRIPT timing, but it does not quantify competitive dynamics, reimbursement changes, or whether Nevro revenue decline is stabilizing, all of which could affect the next earnings read-through.
Background
The article frames GMED’s post-November selloff as a pattern of sharp dips followed by mixed one-year outcomes, then ties the current dip to lowered 2026 revenue guidance and delayed spine product contribution.
Ticker impact
Globus Medical shares are down 19.1% since Nov. 4 after it lowered its 2026 revenue forecast and said SCRIPT spine launches won’t add meaningful growth until 2027.
Likely choppy trading with downside risk until the next earnings update clarifies U.S. Spine growth and any early traction from SCRIPT.
The article’s decision-relevant inputs are the lowered 2026 revenue forecast, the delayed growth timing for SCRIPT into 2027, and the upcoming February 2027 reporting window for U.S. Spine growth.
Market effects
Highlights execution risk in spine device product cycles, where delayed launches can reset growth expectations for medtech peers.
No clear regional spillover beyond U.S. spine revenue focus.
Limited, as the catalysts described are company-specific product and guidance timing.
Counterpoint
Even with stalled sales growth, improving operating margin and cash flow could support valuation and reduce downside if investors re-rate profitability durability.
Key entities
- companyGlobus Medical
Subject of the article, with lowered 2026 revenue forecast and delayed growth contribution from SCRIPT into 2027.
- productSCRIPT
Patient-specific spine implant line management says will not add meaningful growth until 2027.
- business_unitNevro
Pain-treatment company acquired by Globus Medical; revenue fell 25.7% in the quarter cited.




